GAMIDA CELL LTD (GMDA) Forecast, Price Target & Analyst Ratings
NASDAQ:GMDA • IL0011552663
0.0327 USD
-0.01 (-18.25%)
At close: Apr 5, 2024
0.032 USD
0 (-2.14%)
After Hours: 4/5/2024, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GAMIDA CELL LTD (GMDA).
Forecast Snapshot
Consensus Price Target
$4.42
+ 13,416.72% Upside
Next Earnings Forecast
Release DateMay 7, 2024
PeriodQ1 / 2024
EPS Estimate-$0.14
Revenue Estimate3.292M
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.42
Upside
+ 13,416.72%
From current price of $0.03 to mean target of $4.42, Based on 10 analyst forecasts
Low
$2.02
Median
$5.10
High
$6.30
Price Target Revisions
1 Month
0.00%
3 Months
8.33%
Price Target Summary
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.
The average price target has been revised upward by 8.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
GMDA was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about GMDA.
In the previous month the buy percentage consensus was at a similar level.
GMDA was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-01-29 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-12-05 | Needham | Reiterate | Buy -> Buy |
| 2023-11-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-15 | Needham | Reiterate | Buy -> Buy |
| 2023-06-30 | Needham | Reiterate | Buy -> Buy |
| 2023-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-19 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-05-16 | Needham | Reiterate | Buy -> Buy |
| 2023-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-04-20 | Needham | Maintains | Buy |
| 2023-04-19 | HC Wainwright & Co. | Maintains | Buy |
| 2023-04-18 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-28 | Oppenheimer | Maintains | Outperform |
| 2023-03-28 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-22 | Needham | Maintains | Buy |
| 2022-11-15 | Oppenheimer | Maintains | Outperform |
| 2022-09-29 | Needham | Maintains | Buy |
| 2021-11-16 | Needham | Maintains | Buy |
| 2021-11-16 | Oppenheimer | Maintains | Outperform |
| 2021-03-09 | Needham | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 7, 2024
PeriodQ1 / 2024
EPS Estimate-$0.14
Revenue Estimate3.292M
Revenue Q2QN/A
EPS Q2Q49.00%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.30%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
GMDA is expected to report earnings on 5/7/2024. The consensus EPS estimate for the next earnings is -0.14 USD and the consensus revenue estimate is 3.29M USD.
The next earnings revenue estimate has been revised upward by 0.3% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.784M | 15.994M 796.52% | 188.78M 1,080.32% | 378.83M 100.67% | 741.74M 95.80% | 316.32M -57.35% | 1.543B 387.80% | 1.898B 23.01% | |||
| EBITDA YoY % growth | -86.74M -43.21% | -74.55M 14.05% | -70.619M 5.27% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -87.17M -43.07% | -74.99M 13.97% | -72.643M 3.13% | -71.832M 1.12% | 35.73M 149.74% | 167.79M 369.61% | 416.87M 148.45% | 684.93M 64.30% | 967.47M 41.25% | 1.21B 25.07% | |
| Operating Margin | N/A | N/A | -4,071.92% | -449.12% | 18.93% | 44.29% | 56.20% | 216.53% | 62.70% | 63.75% | |
| EPS YoY % growth | -1.52 6.17% | -1.24 18.42% | -0.63 49.19% | -0.57 9.37% | 0.17 130.37% | 0.92 429.41% | 2.24 144.44% | 3.65 62.73% | 5.13 40.50% | 6.40 24.65% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 49.00% | -0.15 52.29% | -0.15 -1,430.00% | -0.16 -295.25% |
| Revenue Q2Q % growth | 3.292M | 3.905M | 4.273M 537.76% | 5.23M 370.75% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.912M 18.73% | -16.878M 10.22% | -18.054M -0.08% | -18.654M -14.98% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
51.21%
EPS Next 5 Year
50.79%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
499.30%
Revenue Next 5 Year
182.44%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
GAMIDA CELL LTD / GMDA Forecast FAQ
Can you provide the average price target for GAMIDA CELL LTD stock?
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.
Can you provide the upcoming earnings date for GAMIDA CELL LTD?
GAMIDA CELL LTD (GMDA) will report earnings on 2024-05-07, after the market close.
Can you provide the consensus estimates for GAMIDA CELL LTD next earnings?
The consensus EPS estimate for the next earnings of GAMIDA CELL LTD (GMDA) is -0.14 USD and the consensus revenue estimate is 3.29M USD.
Can you provide the analyst count for GAMIDA CELL LTD stock?
The number of analysts covering GAMIDA CELL LTD (GMDA) is 10.